VIJAYANSE13 February 2023

Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation

Vijaya Diagnostic Centre Limited

February 13, 2023

To, Listing Department National Stock Exchange Of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400 051 NSE Symbol. VIJAYA

To, The Corporate Relations Department BSE Limited, Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, Mumbai - 400 001 BSE Scrip Code. 543350

Dear Sir/Madam,

Sub: Investor Presentation.

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the presentation that would be used in the Investors / Analysts earnings conference call scheduled to be held on February 14, 2023 at 11:30 a.m. IST.

Please take the information on record.

Thanking you,

For Vijaya Diagnostic Centre Limited

S Suprita Reddy Chief Executive Officer

Encl.: As Above

SUPRITA SURA REDDYDigitally signed by SUPRITA SURA REDDY DN: c=IN, o=PERSONAL, title=8913, pseudonym=56fe28a97d9943a183577de997c5a0d6, 2.5.4.20=aa258bc0eddad165e7d7b0d2e49b6e12df4fc34973ad0cae3aaf2080fd4ec376, postalCode=500033, st=Telangana, serialNumber=315074dfa1901f6701923f5b5a0f21556b5e59ba771f420f4c8e9a31d3d3589e, cn=SUPRITA SURA REDDY Date: 2023.02.13 15:01:43 +05'30' Vijaya Diagnostic Centre Limited

Q3 & 9MFY23 Earnings Presentation

February 13, 2023

Safe Harbour

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Vijaya Diagnostic Centre Limited (the ‘Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Q3 & 9MFY23 Financial Performance

Q3 FY23 – Performance Snapshot

Operational & Financial Highlights – Q3 FY23

2.49 Mn Tests

0.77 Mn Footfalls

117 Centres (opened 5 closed 1)

95% B2C Revenue

COVID INR 9.2 Mn (1%)

INR 1,131.2 Mn Revenue

9.8% (YoY)

89.2% (YoY)

INR 1,121.9 Mn (99%) Non-COVID

INR 442.9 Mn EBIDTA

39.1% EBIDTA Margin

INR 163.6 Mn Profit After Tax

INR 183.5 Mn Normalised Profit After Tax

14.5% PAT Margin

16.2% Normalised PAT1 Margin

Note 1: Normalised PAT is excluding the Notional interest & Depreciation as per IND AS 116, Leases.

Management comment

Commenting on the Q3FY23 results performance, Ms. Suprita Reddy, CEO at Vijaya Diagnostic Centre Ltd. said:

“We are pleased to report steady performance during a seasonally soft quarter for the industry. The volume trends that were slow in the months of October and November, saw a significant improvement in December and we hope to carry this momentum into the upcoming quarter.

Our ongoing efforts to expand the network through the addition of new hubs and spokes has been progressing well. During this quarter, we opened 5 centers including one of its kind facility at Punjagutta. facilities in Punjagutta and Rajahmundry have received an Our newly opened state-of-the-art overwhelmingly positive response from our customers. Additionally, our efforts to improve digital operations are proceeding smoothly, and we anticipate that these initiatives will considerably improve operational efficiency and enhance customer experience across all of our centers.

Looking ahead, the outlook for the diagnostics industry remains positive, with increasing demand for advanced medical services and a growing emphasis on preventive healthcare. We remain confident that our integrated diagnostics offerings, well-established brand and our robust B2C network will enable us to capitalize on the huge market opportunity.”

Key Financial Highlights – Q3 & 9M FY23

(INR Mn)

Revenue from Operations

EBITDA & EBITDA Margin (%)

3,462

3,382

43.2%

40.4%

39.1%

45.0%

39.3%

1,108

1,207

1,131

1,558

1,329

478

487

443

Q3 FY22

Q2 FY23

Q3 FY23

9M FY22

9M FY23

Q3 FY22

Q2 FY23

Q3 FY23

9M FY22

9M FY23

Shift YoY (%)

2.1%

-2.3%

-7.4%

-14.7%

PAT & PAT Margin (%)

Normalised PAT & PAT Margin (%)

22.8%

19.3%

14.5%

24.8%

16.9%

24.2%

20.8%

16.2%

26.2%

18.5%

860

571

905

625

253

233

164

268

251

184

Q3 FY22

Q2 FY23

Q3 FY23

9M FY22

9M FY23

Q3 FY22

Q2 FY23

Q3 FY23

9M FY22

9M FY23

Shift YoY (%)

-35.3%

-33.5%

-31.6%

-31.0%

Revenue Mix – Q3 & 9MFY23

(In %)

Radiology vs. Pathology Breakdown

Non-COVID & COVID Allied Breakdown

Radiology

Pathology

Non Covid

Covid

66%

67%

34%

33%

64%

36%

67%

65%

33%

35%

92%

97%

99%

Q3 FY22

Q2 FY23

Q3 FY23

9MFY22

9MFY23

Q3 FY22

Q2 FY23

Q3 FY23

Non-COVID YoY (%)

COVID YoY (%)

9.8%

-89.2%

B2C Contribution – Q3 FY23 & 9MFY23

Non Covid

Covid

B2B 5%

B2C 95%

15%

85%

9MFY22

Non-COVID YoY (%)

COVID YoY (%)

98%

9MFY23

12.2%

-85.2%

Q3 & 9MFY23 – Key Developments

Recorded its highest ever December monthly volumes in a seasonally soft quarter

0.73

0.76

0.79

0.68

0.87

0.90

0.80

0.88

Non-COVID Test Volumes (# in Million)

• The Company experienced lower volumes during the month of October and November due to the festive season. However, the Company in its operational performance during the month of December

strong uptick

registered a

Apr-22 May-22 Jun-22

Jul-22

Aug-22 Sep-22 Oct-22 Nov-22 Dec-22

VDCL to launch state of the art facility in Tirupathi, Andhra Pradesh

• The 10,000 + sq.ft. facility at Tirupathi, Andhra Pradesh is expected to be inaugurated in February 2023

o The center will be equipped with advanced radiology modalities and equipment, including a 3T MRI, CT scan, Gamma

Camera, basic radiology and an automated lab

Q3 & 9MFY23 - Financial and Operational Discussions (Y-o-Y)

• Revenue from Operations increased by 2.1% YoY to Rs. 1,131 Mn, Non-Covid Revenues grew by 9.8% YoY

• During Q3FY23, the Non-COVID business comprised 99% of total revenue share as against 92% revenue

Financial Performance Q3FY23

•

share in Q3FY22

• Wellness share in Q3FY23 was up at 12.9% as against 8.5% in Q3FY22

• Revenue composition from B2C segment stood at 95%

EBITDA stood at Rs. 443 Mn. EBITDA margin for the quarter was 39.1% as against 43.2% in Q3FY22

o Healthy non covid revenue coupled with operating leverage assisted margin performance despite costs

on account of new centres

PAT stood at Rs. 164 Mn. translating into a PAT margin of 14.5%

• Normalised PAT stood at Rs. 184 Mn. translating into a PAT margin of 16.2%

• Revenue from Operations decreased by 2.3% YoY to Rs. 3,382 Mn, Non-Covid Revenues grew by 12.2% YoY

Financial Performance 9MFY23

•

• Wellness share in 9MFY23 was up at 11.7% as against 6.3% in 9MFY22

• Revenue composition from B2C segment continued to stay strong at 95%

EBITDA stood at Rs. 1,329 Mn. EBITDA margin for 9MFY23 was 39.3%

PAT stood at Rs. 571 Mn. translating into a PAT margin of 16.9% in 9MFY23

• Normalised PAT stood at Rs. 625 Mn. translating into a PAT margin of 18.5% in 9MFY23

Indian Diagnostics Market expected to Grow at a Healthy Trajectory

Indian Diagnostics Market

Segment-wise breakup of Indian Diagnostic Market

(INR Bn)

Radiology

Pathology

980

+13% CAGR

684

472

FY17

FY20

FY23E

+13% CAGR

FY23E 275 - 285

FY20 190 - 195

South India

27% - 29%

FY20

71%-73%

Rest of India

980

43% - 44%

684

43%

+13% - 14% CAGR

+14% CAGR

56% - 57%

+12% CAGR

57%

+12% - 13% CAGR

FY20

FY23E

472

41%

59%

FY17

Source: CRISIL Report

Key Financial Highlights

Cash flow from Operations / EBITDA (%)

Cash & Cash Equivalents (INR Mn)

95.9%

75.8%

74.2%

77.1%

89.5%

2,349

2,493

2,425

2,349

2,425

Q3FY22

Q2FY23

Q3FY23

9MFY22

9MFY23

Q3 FY22

Q2 FY23

Q3 FY23

9M FY22

9M FY23

Working Capital Days1

• Cash flow from Operations stood at Rs. 1,190 mn.

Q3FY22

Q2FY23

Q3FY23

9MFY22

9MFY23

for 9M ended Dec. 31, 2022

-10

-12

-10

• Cash and Cash Equivalents stood at Rs. 2,425 mn.

as on Dec. 31, 2022

• Working Capital Days negative at -10 in Q3FY23

continues

to remain

Note 1: Quarterly Revenue figures are annualized

Key Operational Highlights

Tests Performed (# in Million)

Footfalls (# in Million)

Tests / Footfalls (# in Million)

6.87

7.35

2.67

2.37

3.09

3.22

2.73

3.10

2.58

2.32

2.63

2.49

0.85

0.77

Q3 FY22

Q2 FY23

Q3 FY23

9MFY22

9MFY23

Q3 FY22

Q2 FY23

Q3 FY23

9MFY22

9MFY23

Q3 FY22

Q2 FY23

Q3 FY23

9MFY22

9MFY23

Revenue per Test (INR)

Revenue per Footfall (INR)

477

504

1,464

1,418

1,426

459

454

460

1,303

1,299

Q3 FY22

Q2 FY23

Q3 FY23

9MFY22

9MFY23

Q3 FY22

Q2 FY23

Q3 FY23

9MFY22

9MFY23

• Company recorded steady growth in No. of tests on YoY basis led by Non-COVID customers in 9MFY23

Consolidated Profit & Loss Account – Q3 & 9M FY23

(INR Mn)

Particulars

Q3 FY23

Q3 FY22

Revenue from operations

1,131.2

1,107.8

Cost of materials consumed

Employee benefits expense

Other expenses

EBITDA

EBITDA Margin (%)

Other income

Depreciation and amortization expense

EBIT

Finance costs

Profit before Tax

Tax expenses

Profit before Minority Interest

Minority Interest

Profit after Tax (PAT)

PAT Margin (%)

EPS – Basic (INR) *

Normalised PBT

Normalised PBT Margin (%)

Normalised PAT

Normalised PAT Margin (%)

136.7

197.3

354.3

442.9

39.1%

35.6

202.8

275.6

55.4

220.2

55.6

164.6

0.9

163.6

14.5%

1.6

246.8

21.8%

183.5

16.2%

Y-o-Y

2.1%

-16.2%

8.3%

24.7%

-7.4%

Q2 FY23

Q-o-Q

9M FY23

9M FY22

Y-o-Y

1,207.5

-6.3%

3,382.3

3,461.7

-2.3%

166.5

197.4

356.1

487.4

-17.9%

0.0%

-0.5%

-9.1%

433.5

589.5

1,030.1

536.2

514.6

852.5

-19.2%

14.6%

20.8%

1,329.2

1,558.3

-14.7%

163.0

182.2

284.3

478.3

43.2%

-410 bps

40.4%

-130 bps

39.3%

45.0%

-570 bps

32.0

130.1

380.2

41.8

338.5

83.9

254.6

1.7

252.9

22.8%

2.5

359.1

32.4%

268.4

24.2%

11.1%

56.0%

-27.5%

32.7%

-34.9%

-33.7%

-35.4%

-48.4%

-35.3%

-830 bps

-35.9%

-31.3%

-1,060 bps

-31.6%

-800 bps

33.0

159.0

361.4

48.7

312.7

78.0

234.7

1.4

233.3

19.3%

2.3

335.8

27.8%

250.6

20.8%

7.7%

27.6%

-23.8%

13.7%

-29.6%

-28.7%

-29.9%

-36.6%

-29.9%

-480 bps

-28.1%

-26.5%

-600 bps

-26.8%

-460 bps

96.3

503.6

921.9

151.8

770.1

195.3

574.8

3.4

571.4

16.9%

5.6

841.8

24.9%

624.9

18.5%

96.4

374.1

1,280.7

121.2

1,159.5

291.7

867.8

8.2

859.7

24.8%

8.4

-0.1%

34.6%

-28.0%

25.3%

-33.6%

-33.0%

-33.8%

-58.1%

-33.5%

-790 bps

-33.3%

*Not annualized

1,220.7

-31.0%

35.3%

905.4

26.2%

-1,040 bps

-31.0%

-770 bps

Normalised PBT/PAT is excluding the Notional interest & Depreciation as per IND AS 116, Leases.

Company Overview

Vijaya at a Glance

Vijaya Diagnostic Centre Limited is the largest integrated diagnostic chain in South India with 117 state-of-the-art centres spread across 19 cities

Mission

Our Mission is to make the patient’s medical journey faster, more transparent and more accurate. We are committed to deliver exceptional diagnostic solutions to every patient and physician

40+ Years of Experience

Experience in delivering Quality Diagnostic Service at affordable prices

117 Centres

State-of-the-art Facilities with Best-in-class Technology

19 Cities across India

200+ Doctors

Vision

Largest integrated player in South India

Radiologists, Pathologists & Microbiologists

Our Vision is to provide reliable and accurate to our customers, at diagnostic services customer-centric in a affordable prices, manner. We strive to provide the best service possible. We are continually raising our own bar through the latest technology, continuous improvement and recruitment of high calibre technicians and professional

~3.6 Mn Footfalls

~9.3 Mn Tests

Trusted by every Age group

Most preferred Diagnostic Centre

Footfalls & Tests for 12 months ending Mar 2022

Quality

Reliable & Accurate Diagnostics

at Affordable Prices

Our Journey

Vijaya Diagnostic Centre incorporated in Hyderabad

Recognized as one of the Best Imaging centres in Hyderabad by The Week

Awarded Brand of the year in diagnostic services by The CEO Magazine and Telangana Healthcare Leadership award

One of the earliest private diagnostic service providers to be approved for COVID RT- PCR testing by ICMR*

Awarded one of the Best Healthcare Brands 2022 by The Economic Times

Won the Healthcare Leadership Awards 2022

Awarded Pride of India Brands Award – The Best of South Awards 2022

1981

2012

2018

2020

2022

2008

2016

2019

2021

First independent diagnostic centre in South India to offer PET CT from Wipro GE Healthcare Pvt. Ltd.

Investment by Karakoram Limited and Kedaara Capital Alternative Investment Fund – Kedaara Capital AIF1

Awarded Best Diagnostic Centre – India by Times Healthcare Achievers Group

Successfully listed on Indian Stock Exchanges (NSE & BSE)

First independent diagnostic centre in Telangana to get Revolution ACT 50 slice CT from Wipro GE Healthcare Pvt. Ltd

*ICMR: Indian Council of Medical Research; NSE: National Stock Exchange, BSE: Bombay Stock Exchange

At the Forefront of Introducing New Technologies

1981

Ultrasound & Echocardiography

1986

Nuclear Medicine facility

1993

Fourth Generation CT Scan

1994

Offer Mammography

2006

Hawkeye Gamma Camera with SPECT

2003

Automated Microbiology Culture

2000

Real Time RT-PCR Assays & Flow Cytometry

1999

Bone Densitometry

2007

Cardiac CT & 3.0 Tesla MRI

2009

HPV-DNA HC2 test in South India

2011

Automated TB identification & Sensitivity in South India

2012

Liquid Based Cytology (Thin Prep) in Andhra Pradesh (AP)

2019

3D Mammography with Advanced Technology

2019

USG-ECHO for Cardiology & Advanced CBCT in South India

2017

Droplet Digital PCR (ddPCR) & Adv. PET CT in South India

2013

iQ200 Automated Iris Urine with Analyzer Microscopy & Siemen’s Accuson Elastography

2019

DNA fragmentation Index test in semen

2020

Integrated modular solution for Immunoassay & Chemistry assays

2020

COVID testing by RT-PCR in Telangana & AP

2021

Philips DS Achieva with Ambient Experience

2022

‘Walk-in Walk-out Dual source CT’ and ‘BioMatrix 3T’

Our Pillars of Strength

One of the leading players in India’s high growth diagnostics market

Integrated diagnostics provider offering one-stop solution

High brand recall driving customer stickiness

Robust technical capabilities and state-of-the-art technology

Experienced Board and strong management team

One of the leading players in India’s high growth diagnostics market

Telangana and Andhra Pradesh Market Size

Vijaya’s Core Geographies

Telangana and Andhra Pradesh (44 - 46% of South India)

+14% CAGR

(INR Bn)

120 -130

FY17

FY20

FY23E

Growth Drivers:

•

Rising NCDs in the states

Increasing share of aged population

Rising health awareness

Increasing health insurance penetration

Conducive government healthcare schemes

Dominant Position in Telangana & Andhra Pradesh

Nizamabad

Karimnagar

Mancherial

Hanamkonda Kazipet

Warangal

Sangareddy

Shamshabad

Shadnagar

Wanaparthy

Hyderabad & Secunderabad

Kurnool

Nandyal

Nellore

Vishakhapatnam

Rajahmundry

NCD: Non Communicable diseases

Source: CRISIL Report

Integrated Diagnostic service provider with extensive network…

Customers

Samples

Customer (Walk-in) Home Collection B2B Hospitals & Labs

Vijaya Diagnostic Centre

Flagship Centre #1

Hubs #26

Spokes #90

National Reference Lab

Reference Lab

#15

Sample Flow Patient Flow

Flagship Centre = Lab Sample Collection + Basic Radiology + Complete Advanced Radiology (MRI, CT Scan, SPECT & PET CT) Hubs = Lab Samples Collection + Basic Radiology + Advanced Radiology (MRI / CT Scan / SPECT) Spokes = Lab Samples Collection + Basic Radiology Basic Radiology = ECG / X-ray / USG / Mammography / BMD / TMT / 2D Echo / EEG / ENMG / Endoscopy, etc.

…offering One-Stop Solutions for Pathology & Radiology

Complete Range of Diagnostic Services under One Roof Comprehensive and high quality integrated diagnostic services through our operational network

High brand recall driving customer stickiness

Customer Centric Approach

Quality Diagnostic Services

B2C Revenue

90%

93%

92%

94%

Higher brand recall

High share of walk-in customers

Sticky individual customer

(INR)

FY19

FY20

FY21

FY22

Operational Metrics

“One of the Best Healthcare Brands 2021” by The Economic Times in 2021

“For excellence in Quality and Accuracy” under the category Leading Diagnostics company with Excellence in Quality and Safety at the Diagnostics Leadership Summit in 2021

1,228

1,214

1,431

1,276

454

475

631

562

FY19

FY20

FY21

FY22

Revenue per footfall

EBITDA per footfall

Robust Technical Capabilities with State-of-the-art IT Infrastructure

CT Machines

MRI Machines

PET CT / Gamma machines

200+

Radiologists, Lab Doctors & Physicians

NABH Accreditations

NABL Accreditations

Key Suppliers

• Long standing relationship with medical technology vendors

• At the forefront of introducing new tests by

adopting the latest medical

technologies

• Among the first diagnostic service provider in South India to offer PET-CT scan

in 2008

Advanced Software to Manage Clinical Data

Advance Laboratory Information Management System (LIMS)

Fully Integrated Radiology Information Systems (RIS) and Picture Archive and Communication Systems (PACS)

Front end IT infrastructure enabling…

Standardization across our operations

incidence

Reduce errors due Human Intervention

of Low

Monitor Operations

Technical

Closely track key performance metrics and maintain the Turn- Around Time (TAT)

Provide Uniform Experience to booking from customers accessing to appointments reports online

Experienced Board of Directors

Dr. S Surendranath Reddy - Executive Chairman ▪ Founder of Vijaya with 40+ years of experience in building Vijaya as South

India’s largest integrated diagnostic chain

▪ Holds Bachelor’s degree in Medicine and Provisional degree of Doctor of

Medicine in Radiology

Dr. D Nageshwar Reddy - Non-executive, Independent Director

▪ Chairman of Asian Institute of Gastroenterology (AIG), Hyderabad ▪ Awarded Padma Shri and Padma Bhushan by Government of India ▪ D.M in Gastroenterology from PGIMER Chandigarh

S Geeta Reddy - Non-Executive Director

▪ Enrolled as advocate with Andhra Pradesh High Court in 1986

▪ Holds a Bachelor’s degree in Law from Osmania University

Shekhar Prasad Singh - Non-executive, Independent Director

▪ Ex-Chief Secretary to Government of Telangana

▪ Retired IAS officer of 1983 batch

Satyanaryana Murthy Chavali - Non-executive, Independent Director

▪ Ex-CEO of Aurigene Discovery Technologies Ltd.

▪ Holds BTech from IIT, Madras and MBA from IIM, Bangalore

Sunil Chandra Kondapally - Executive Director

▪ Been with Vijaya since 2002 and 17+ years of experience in healthcare

▪ Holds Bachelor’s degree in Electrical Engineering from Florida State

Dr. Manjula Anagani - Non-executive, Independent Director

University

▪ Clinical Director and Head of Department of centre of women and childcare at

Care hospitals

▪ Awarded Padma Shri by Government of India ▪ MD in Obstetrics and Gynecology from N.T.R. University of Health Sciences

Strong Management Team

Dr. S. Surendranath Reddy

Mr. Sunil Chandra Kondapally

Ms. Suprita Reddy

Mr. Narasimha Raju K.A

Executive Chairman

Executive Director

Chief Executive Officer

Chief Financial Officer

▪ 40+ years of experience in building Vijaya as South India’s integrated diagnostic largest chain

▪ Holds Bachelor’s degree in Provisional and Medicine degree of Doctor of Medicine in Radiology

▪ He is a life member of the and

Radiological

Indian Imaging Association.

▪ With Vijaya since incorporation and experienced in operations, finance, quality accreditation, marketing network expansion departments

and

▪ 17+ Years of experience in healthcare industry & founded Trikona Pharmaceuticals Pvt. Ltd. (2016) and QPS Bioserve India Pvt. Ltd. (2004)

operations

▪ With Vijaya since 2003 and heads overall strategy, clinical and excellence, expansion of the company ▪ Awarded Women Leadership Award in Healthcare by ABP in 2019

▪ Holds bachelors degree in from Osmania

commerce University

▪ Holds bachelor’s degree

electrical engineering Florida State University

in from

▪ Associated with Vijaya from June 2017 to Nov 2020 and rejoined in March 2021

▪ 14+ years of experience in reporting, financial and

audit, regulatory accounting advisory

compliance

▪ Previously worked with SR Baltliboi & Co., NSL Renewable Power Pvt. Ltd. etc

▪ Holds bachelor’s degree of commerce from Osmania University and member of the Chartered of Institute Accountants of India

Awards & Accolades

Best Healthcare Brands 2022

Healthcare Leadership Awards 2022

Pride of India Brands Award 2022

One of the Best Healthcare Brands 2021

Indo Global Award for Healthcare Excellence

Company of the Year - Healthcare

2022 Presented by The Economic Times

2022 Presented by eHealth Magazine

2022 Presented by The Best of South Awards

2021 Presented by The Economic Times

2021 Presented by Indian Economic Development & Research Association

2021 Presented by TV9 Network and SAP

Leading Diagnostic Chain of the Year

India’s Greatest Brands 2020- 21 Pride of Nation

Leading Diagnostics with Excellence in Quality & Safety

Most Trusted and Best Quality Diagnostic services in India

Healthcare Entrepreneur of the Year – Dr. Surendra Reddy

2021 Presented by Diagnostic Leadership Summit

2021 Presented by United Research Services

2021 Presented by Diagnostic Leadership Summit

2020 Presented by Times Healthcare Achievers

2019 Presented by Six Sigma Healthcare

Fastest Growing Brands (Pride of the Nation)

Best Diagnostic Centre of the Year

Leading Chain of Diagnostics & Imaging

Best Diagnostic Service Provider of the Year

Most Trusted Diagnostic Centre of the Year

Telangana Healthcare Leadership Awards

2019 Presented by United Research Services

2019 Presented by Times Healthcare Achievers

2019 Presented by Indian Medical Association, Telangana state and Messe India

2019 Presented by Six Sigma Healthcare

2019 Presented by Indo-Arab Leaders Summit & Awards

2018 Presented by Telangana Government

Shareholding Pattern as of 31st Dec 2022

Others

FII’s

6.5%

24.3%

14.2%

DIIs

As on 31st December 2022 DII’s: Mutual Funds, AIF’s and QIB’s Others: Retail, Bodies Corporate and others

Promoter & Promoter group

55.0%

Marquee Institutional Investors

Wasatch Advisors

Nippon Life India

Aberdeen Standard Investments

Axis Mutual Fund

Fidelity Group

DSP Healthcare Fund

Abu Dhabi Investment Authority

Goldman Sachs

Strategy Going Forward

Deepen Footprint in our Core Markets - Telangana & Andhra Pradesh

Nizamabad

Sangareddy

Mancherial

Karimnagar

Hanamkonda Kazipet Warangal

Shamshabad Shadnagar

Wanaparthy

Kurnool Nandyal

Hyderabad & Secunderabad

Vishakhapatnam

Rajahmundry

Nellore

Leveraging Existing Presence

Given under-penetration of diagnostic market, we will continue to focus on

Opening additional diagnostic centres through owned model

Expanding network through setting up spokes and hubs in existing catchment areas

Adding reference laboratories in our existing core geographies

Consolidate Leading Position

Given our significant presence and operational experience in Telangana and Andhra Pradesh, we intend to deepen our penetration and increase customer base by

Enhancing laboratory capacity and test menu by adding latest technologies

Offering value added services

Physician engagements (by conducting continuous medical education programs)

Expand in Adjacent Geographies & East India

Network (FY22)

South India Strategy

◼ Expand in concentric circles given our

hub and spoke model

◼ Establish presence in adjacent

geographies

◼ Identified key cities and towns which are

underserved and our brand is well- regarded

◼ Wider geographic reach will expand our

customer base leading to better profitability by leveraging our infrastructure

Hyderabad

Rest of Telangana and AP

Others

East India Strategy

◼ Expand presence in East India given

growing demand

◼ Replicate our successful hub and spokes

model in East India

◼ Established a hub in Kolkata and plan is to

set up additional diagnostic centres around it

◼ Hence, Kolkata to be our focus area for

medium to long term growth

AP: Andhra Pradesh

Continued Focus on Providing Customer Centric Services and Offerings

Preventive and Wellness Testing to Boost Demand for Diagnostics

FY20E

Industry Size

FY23P

CAGR: ~20%

101-108

61-68

Rest of the market 90%

Wellness & Preventive 9% - 10%

Wellness & Preventive 11%

Rest of the market 89%

FY20

FY23

Key Drivers

Our Strategy

◼ Increasing chronic and lifestyle diseases

◼ Increase diagnostic services by offering additional preventive and wellness services through adoption of

new cutting-edge diagnostic testing technology

◼ Corporate tie-ups

◼ Increasing disposable income

◼ Increasing service offerings

◼ Providing home collection services and point-of-contact testing to complement walk-in

◼ Expand specialty tests, disease specific profiles and provide customized packages

◼ Grow our corporate customer base by catering to their needs

◼ Expansion of chronic disease management and wellness programs

Source: CRISIL Report

Financial & Operational Highlights

Robust Operational Metrics

Diagnostic Centre (Nos)

Footfalls (Mn)

Tests Performed (Mn)

2.38

2.79

2.63

3.62

6.99

7.91

7.09

9.32

FY19

FY20

FY21

FY22

FY19

FY20

FY21

FY22

FY19

FY20

FY21

FY22

Test per Footfall (Nos)

Revenue per Test (INR)

Revenue per Footfall (INR)

Impact of COVID-19

2.93

2.83

2.69

2.57

419

428

531

496

1,228

1,214

1,431

1,276

FY19

FY20

FY21

FY22

FY19

FY20

FY21

FY22

FY19

FY20

FY21

FY22

Consistent Financial Performance

(INR Mn)

Revenue

CAGR:16%

3,388

3,767

2,926

4,624

EBIDTA

PAT

CAGR:24%

2,037

1,660

1,326

1,081

CAGR:34%

845

1,097

625

459

FY19

FY20

FY21

FY22

FY19

FY20

FY21

FY22

FY19

FY20

FY21

FY22

EBIDTA Margin (%)

710 bps

44.1%

39.1%

37.0%

PAT Margin (%)

800 bps

22.4%

23.7%

18.5%

15.7%

FY19

FY20

FY21

FY22

FY19

FY20

FY21

FY22

Sustainable Cash Generation & Increasing Return Ratios

Cash & Cash Equivalents

CFO / EBIDTA (%)

(INR Mn)

1,729

1,215

2,277

2,467

84%

80%

78%

77%

FY19

FY20

FY21

FY22

FY19

FY20

FY21

FY22

RoCE Pre-Cash (%)

RoE (%)

30%

33%

43%

38%

22%

23%

FY19

FY20

FY21

FY22

FY19

FY20

FY21

FY22

ROCE (Pre-cash): PBIT ex Other income / (Total Assets – Cash – Current Liabilities)

CFO = Cash flow from Operations

Annexure

Consolidated Profit & Loss Account

(INR Mn)

Particulars

Revenue from operations

Cost of materials consumed

Employee benefits expense

Other expenses

EBITDA

EBITDA %

Other income

Depreciation and amortization expense

EBIT

Finance costs

Profit before Tax

Tax expenses

Profit after Tax before Minority Interest

Minority Interest

Profit after Tax

PAT %

EPS – Basic (INR)

FY22

4,624

715

707

1,165

2,037

44.1%

128

527

1,638

165

1,474

367

1,107

1,097

23.7%

10.76

FY21

3,767

571

574

962

1,660

44.1%

118

505

1,274

152

1,121

270

851

845

22.4%

8.28

FY20

3,388

439

624

999

1,326

39.1%

154

492

988

154

834

209

625

18.5%

6.13

FY19

2,926

405

539

901

1,081

37.0%

104

396

789

135

653

190

463

459

15.7%

4.50

Consolidated Balance Sheet

(INR Mn)

Assets

Mar-22 Mar-21 Mar-20 Mar-19

EQUITY AND LIABILITIES

Mar-22 Mar-21 Mar-20 Mar-19

NON-CURRENT ASSETS Property, plant and equipment Capital work-in-progress Goodwill Other intangible assets Right of use asset Intangible assets under development Financial assets - Investments - Other financial assets Deferred tax assets Income tax assets Other assets

CURRENT ASSETS Inventories Financial assets - Investments - Trade receivables - Cash and cash equivalents - Bank balances other than Cash and cash equivalents - Loans - Other financial assets Other current assets

4,436 1,966 341 53 14 1,672 1

0 75 89 2 223

3,022 1,358 82 53 6 1,260 12

0 122 61 6 61

2,959 1,398 93 53 10 1,254 4

0 55 16 9 67

2,689 1,437 27 69 7 1,079 -

0 43 12 8 7

2,699 43

2,388 26

1,865 28

1,374 22

542 98 110

276 64 67

1,813

1,876

0 51 41

0 52 27

547 80 556

626

1 5 22

688 91 96

430

4 26 17

EQUITY

Equity share capital

Instruments entirely equity in nature

Other equity

4,695

102

3,592

2,741

2,069

4,593

3,547

2,696

2,000

NON-CURRENT LIABILITIES

1,778

1,377

1,494

1,422

Financial liabilities

- Borrowings

- Lease liabilities

- Other financial liabilities

Provisions

Other liabilities

CURRENT LIABILITIES

Financial liabilities

- Borrowings

- Lease liabilities

- Trade payables

- Other financial liabilities

Income tax liabilities

Provisions

Other liabilities

1,703

1,265

221

1,196

315

1,034

661

440

589

572

126

216

248

101

222

217

224

218

204

TOTAL ASSETS

7,135

5,409

4,824

4,063

TOTAL EQUITY AND LIABILITIES

7,135

5,409

4,824

4,063

Consolidated Cash Flow Statement

(INR Mn)

Particulars Cash Flow from Operating Activities Profit before Tax Adjustment for Non-Operating Items Operating Profit before Working Capital Changes Changes in Working Capital Cash Generated from Operations Less: Direct Taxes paid Net Cash from Operating Activities Purchase and construction of property, plant and building (net) Investments (net) Others Cash Flow from Investing Activities Cash Flow from Financing Activities Net increase/ (decrease) in Cash & Cash equivalent Cash & Cash Equivalents at the beginning of the period Cash & Cash equivalents at the end of the period

Cash and Cash Equivalents

Particulars

Investments*

Cash and cash equivalents

Bank balances other than Cash and cash equivalents

Total

Mar-22

Mar-21

Mar-20

Mar-19

1,474 572 2,046 -67 1,975 -399 1,580 -1,223 -127 120 -1,226 -306 44 67 110

1,121 534 1,655 -46 1,609 -312 1,297 -312 -1,033 47 -1,298 -488 -489 556 67

834 492 1,326 -32 1,294 -233 1,061 -375 11 57 -306 -295 460 96 556

653 431 1,084 8 1,092 -187 905 -591 -314 6 -898 -72 -65 161 96

Mar-22

Mar-21

Mar-20

Mar-19

543

110

1,813

2,467

335

1,876

2,277

547

556

626

1,729

688

430

1,215

*Current investments + investments with maturity more than 12 months (part of other non-current financial assets)

THANK YOU

Company

Investor Relations Advisors

Vijaya Diagnostic Centre Limited (VDCL)

Citigate Dewe Rogerson (CDR India)

Mr. Siva Rama Raju – Head of Strategy +91 90597 00749 / +91 99485 95555

sivaramaraju.v@vijayadiagnostic.in ir@vijayadiagnostic.in

www.vijayadiagnostic.com

Mr. Anoop Poojari / Mr. Devrishi Singh

Tel: +91 98330 90434 / +91 98205 30918

anoop@cdr-india.com devrishi@cdr-india.com

#6-3-883/F, Ground Floor, FPAI Building, Punjagutta, Officers Colony, Near Topaz Building, Hyderabad-500082, Telangana, India.

← All Transcripts VIJAYA Stock Page →

Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation

Market Movers